Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03855137 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 778
- Enrollment target
NCT03855137 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 778 participants.
The verdict
NCT03855137, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 778 participants
- Enrollment target
Study Summary
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
Interventions
- DRUG Placebo
- DRUG Atogepant 60 mg
- DRUG Atogepant 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 778 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03855137
The ClinicalTrials.gov registry entry for NCT03855137 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 778 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03855137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03855137 about?
NCT03855137 is a clinical study titled "Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine". This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
What is the current status of trial NCT03855137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 778 participants. The study started on 2019-03-11. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT03855137?
The interventions under investigation include: Placebo (DRUG), Atogepant 60 mg (DRUG), Atogepant 30 mg (DRUG).
Who is sponsoring clinical trial NCT03855137?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.